Summary
The claims are about pricing/out-of-pocket cost and market/payer dynamics, which are not addressed in the supplied ILARIS (canakinumab) FDA prescribing information excerpts. Therefore, none of the claims can be supported or evaluated as on-label content from the provided label.
Category Scores
Accurate Statements
Unsupported Statements
Ilaris (canakinumab) pricing isn’t published as a single "one price" number.
Not supported or mentioned in the provided FDA prescribing information excerpts.
The net price a patient or insurer pays for Ilaris can vary based on dosing schedule, treatment duration, contract terms, rebates, and whether the purchase is through specialty distributors.
Not supported or mentioned in the provided FDA prescribing information excerpts.
Public references for Ilaris often focus on list price or estimated ranges rather than a guaranteed out-of-pocket cost.
Not supported or mentioned in the provided FDA prescribing information excerpts.
Out-of-pocket cost for Ilaris depends on insurance coverage (commercial vs. government plans).
Not supported or mentioned in the provided FDA prescribing information excerpts.
Out-of-pocket cost for Ilaris depends on prior authorization requirements.
Not supported or mentioned in the provided FDA prescribing information excerpts.
Out-of-pocket cost for Ilaris depends on copay assistance or patient support programs.
Not supported or mentioned in the provided FDA prescribing information excerpts.
Out-of-pocket cost for Ilaris depends on deductible status and coinsurance.
Not supported or mentioned in the provided FDA prescribing information excerpts.
Out-of-pocket cost for Ilaris depends on whether the plan uses a specialty pharmacy and the dispensing channel.
Not supported or mentioned in the provided FDA prescribing information excerpts.
Specialty biologics like Ilaris are usually billed under specialty pharmacy benefit rules.
Not supported or mentioned in the provided FDA prescribing information excerpts.
Out-of-pocket costs for Ilaris can be very different even for the same patient profile depending on plan design.
Not supported or mentioned in the provided FDA prescribing information excerpts.
Price movement for Ilaris can happen when biosimilar or competitive products enter.
Not supported or mentioned in the provided FDA prescribing information excerpts.
Price movement for Ilaris can happen when market/payer negotiations change.
Not supported or mentioned in the provided FDA prescribing information excerpts.
Patent and exclusivity timelines can matter for competitive pressure that may influence Ilaris pricing.
Not supported or mentioned in the provided FDA prescribing information excerpts.
Contradictions
Important Omissions
Any on-label FDA prescribing information content relevant to the claims (e.g., indication, dosage, contraindications, warnings/precautions, drug interactions, adverse reactions).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The supplied claims relate to pricing/access logistics rather than drug safety, efficacy, dosing, contraindications, or interactions; no direct conflict with safety-relevant label content was identified, but the claims cannot be verified against the provided label.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Not Applicable to Provided Label
Primary Issue
Claims are outside the scope of the supplied FDA prescribing information excerpts and cannot be supported by or mapped to them.
Suggested Improvement
Limit responses to label-supported topics (indications, dosing/administration, contraindications, warnings/precautions, drug interactions, adverse reactions, and approved use in populations) or provide label text that addresses pricing/out-of-pocket costs (if available).